Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Peter A McSweeney1, Richard A Nash, Keith M Sullivan

  • 1University of Colorado Health Sciences Center, Denver 80262, USA. peter.mcsweeney@uchsc.edu

Blood
|August 15, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A case of subacute phosphate nephropathy caused by oral sodium phosphate].

Zhonghua nei ke za zhi·2024
Same author

[Epidemic characteristics of mycoplasma pneumoniae infection and drug-resistant gene mutations in hospitalized children aged 0-17 in Ningbo City from 2019 to 2023].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2024
Same author

[Analysis on early predictors of respiratory depression in patients with glufosinate poisoning].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2024
Same author

[Progress in IgA-dominant infection-related glomerulonephritis].

Zhonghua nei ke za zhi·2023
Same author

[Clinical significance of intersphincteric resection related anatomy effect on surgical safety].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2023
Same author

Moisture retention of glycerin solutions with various concentrations: a comparative study.

Scientific reports·2022

High-dose immunosuppressive therapy (HDIT) shows promise for severe systemic sclerosis (SSc). While toxicities exist, modified approaches improved outcomes in skin and disability, warranting further study.

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Background:

  • Systemic sclerosis (SSc) is a severe autoimmune disease with limited treatment options.
  • High-dose immunosuppressive therapy (HDIT) is an investigational approach for severe autoimmune conditions.

Purpose of the Study:

  • To evaluate the safety and efficacy of HDIT in patients with poor-prognosis SSc.
  • To assess treatment-related toxicities and disease response after HDIT.

Main Methods:

  • Nineteen SSc patients received HDIT including total body irradiation (TBI), cyclophosphamide, and antithymocyte globulin.
  • Hematopoietic rescue was achieved with autologous blood stem cells.
  • Lung shielding was introduced during TBI in later patients to mitigate pulmonary toxicity.

Related Experiment Videos

Main Results:

  • The 2-year estimated survival rate was 79%, with deaths due to treatment complications or disease progression.
  • Pulmonary toxicity was reduced in patients receiving lung shielding during TBI.
  • Significant improvements in skin scores (modified Rodnan) and disability (mHAQ-DI) were observed in 12 of 12 evaluable patients at 1 year.

Conclusions:

  • HDIT, despite initial toxicities, demonstrates promising efficacy for SSc, particularly with modified protocols.
  • Observed responses in skin and disability scores surpass those of existing therapies.
  • Further evaluation in prospective randomized studies is recommended for HDIT in SSc.